Seattle Genetics

Seattle Genetics is a biotechnology company that is focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Its antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.
The Company also is advancing a deep pipeline of innovative therapies for blood cancers and solid tumors, including vadastuximab talirine (SGN-CD33A) an ADC in the pivotal phase 3 CASCADE clinical trial for acute myeloid leukemia (AML), enfortumab vedotin (ASG-22ME) for urothelial cancer under its collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer. Its programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.

Revenue(FY, 2017)

$482.3 M

Market capitalization(2018-06-14)

$10.4 B

Type

Public

Bothell, US

Founded

1998

Size (employees)

1,100 (est)+24%

Website

seattlegenetics.com

Seattle Genetics was founded in 1998 and is headquartered in Bothell, US

Report incorrect company information

Key People/Management at Seattle Genetics

Clay Siegall

President, Chief Executive Officer and Chairman of the Board

Roger D. Dansey M.D

Chief Medical Officer

Vaughn Himes

CTO

Todd Simpson

CFO

Darren Cline

Executive VP, Commercial

Jean I. Liu J.D

General Counsel, Executive VP, Legal Affairs

Report incorrect company information

Seattle Genetics Office Locations

Seattle Genetics has offices in Zug and Bothell

Bothell, US (HQ)

21717 30th Dr SE

Zug, CH

19 Dammstrasse, Suite 403–406

Show all (2)

Report incorrect company information

Seattle Genetics Financials and Metrics

Seattle Genetics Financials

Seattle Genetics's revenue was reported to be $482.25 m in FY, 2017

Summary

USD
Revenue (Q1, 2018)	140.6 m
Gross profit (Q1, 2018)	130.2 m
Gross profit margin (Q1, 2018), %	92.6%
Net income (Q1, 2018)	(111.7 m)
EBIT (Q1, 2018)	(93.8 m)
Market capitalization (14-Jun-2018)	10.4 b
Closing share price (14-Jun-2018)	65.5
Cash (31-Mar-2018)	186.9 m

Seattle Genetics's current market capitalization is $10.4 b.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	269.3 m	286.8 m	336.8 m	418.1 m	482.3 m
Revenue growth, %		6%	17%	24%
Cost of goods sold	13.8 m	17.5 m	24.5 m	28.2 m	34.8 m
Gross profit	255.5 m	269.2 m	312.3 m	390 m	447.5 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Revenue	71 m	68.3 m	68.3 m	75.9 m	82.2 m	77.1 m	84.1 m	111.2 m	95.4 m	106.3 m	109.1 m	108.2 m	140.6 m
Cost of goods sold	3.5 m	3.7 m	4.1 m	4.7 m	5.2 m	5.9 m	6.6 m	5.9 m	6.9 m	7.4 m	7.5 m	8.1 m	10.4 m
Gross profit	67.4 m	64.6 m	64.2 m	71.1 m	76.9 m	71.2 m	77.4 m	105.2 m	88.5 m	98.9 m	101.7 m	100.2 m	130.2 m
Gross profit Margin, %	95%	95%	94%	94%	94%	92%	92%	95%	93%	93%	93%	93%	93%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	64.1 m	56.9 m	102.3 m	108.7 m	160.9 m
Accounts Receivable	29.5 m	39.2 m	52.9 m	61.9 m	84.8 m
Inventories	27.1 m	43.5 m	57 m	68.1 m	60 m
Current Assets	437.3 m	408 m	771.1 m	734.6 m	577.1 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	119.5 m	44.8 m	38.8 m	50.2 m	62.6 m	79 m	614.1 m	119.5 m	192.1 m	131 m	75.8 m	197.1 m	186.9 m
Accounts Receivable	29.2 m	37.9 m	34.9 m	43.8 m	49.6 m	45.3 m	63.5 m	52.4 m	57.7 m	65.1 m	73.7 m	71.9 m	118.6 m
Inventories	26 m	29 m	30.5 m	37.5 m	43.1 m	47.5 m	44.5 m	60.1 m	71.7 m	71.6 m	60.7 m	69.2 m	71.9 m
Current Assets	435 m	429.4 m	423 m	429.2 m	396.9 m	354.1 m	852.8 m	736.1 m	750.6 m	744.3 m	656.2 m	616 m	634.5 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(62.5 m)	(76.1 m)	(120.5 m)	(140.1 m)	(125.5 m)
Depreciation and Amortization	8.6 m	12.5 m	14.5 m	18 m	24.3 m
Inventories	10.7 m	(16 m)	(14 m)	(11.2 m)	8.1 m
Accounts Payable					19.1 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(23.7 m)	(16.3 m)	(17.6 m)	(15.6 m)	(21.7 m)	(47.5 m)	(26.4 m)	(20.5 m)	(32.7 m)	(31.8 m)	(60 m)	(111.7 m)
Depreciation and Amortization												7 m
Inventories			30.5 m	37.5 m	43.1 m	47.5 m	44.5 m	60.1 m	71.7 m	71.6 m		(11.9 m)
Accounts Payable												(28.9 m)